

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Charles A. Peloquin		POSITION TITLE Director, Infectious Disease Pharmacokinetics Lab	
eRA COMMONS USER NAME			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Connecticut, Storrs, CT	BS	1981	Pharmacy
Duke University Medical Center, Durham, NC	Residency	1983	Clinical Pharmacy
Philadelphia College of Pharmacy, PA	Pharm.D.	1986	Clinical Pharmacy
Millard Fillmore Hospital, Buffalo, NY	Fellowship	1988	Infectious Disease and Pharmacokinetics

**A. Positions and Honors****Positions and Employment**

- 2009-present Director, Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and The Emerging Pathogens Institute, University of Florida
- 1988-2009 Director, Infectious Disease Pharmacokinetics Laboratory, Department of Medicine, National Jewish Health
- 9/88-present Clinical Professor of Pharmacy / 1993: Clinical Professor of Medicine, University of Colorado Schools of Pharmacy and Medicine, Denver, CO
- 1991-present Consultant, Public Health Service and Food Drug Administration, Rockville, MD

**Honors**

- American College of Clinical Pharmacy Infectious Disease Research Fellow 1987-88
- University of Connecticut Honors Scholar
- Consultant, Advisory Council for the Elimination of Tuberculosis, Department of Health and Human Services

**B. Selected peer-reviewed publications (numbered in personal sequence of publication).**

2. **Peloquin CA**, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organisms, MIC, and clinical condition on bacterial eradication. Archives of Internal Medicine 1989; 149: 2269-2273.
5. **Peloquin CA**, James GT, McCarthy EA, Goble M. Pharmacokinetics of ethionamide suppositories. Pharmacotherapy 1991; 11: 359-363.
7. **Peloquin CA**, Henshaw TL, Huitt GA, Berning, SE, Nitta AT, James GT. Pharmacokinetic evaluation of p-aminosalicylic acid granules. Pharmacotherapy 1994; 14: 40-46, and Pharmacotherapy 1994; 14:(4) P-2.
14. **Peloquin CA**, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, Berning SE, Gerena GT. Incidence of low anti-tuberculosis drug concentrations in patients with AIDS. Annals of Pharmacotherapy 1996; 30: 919-925.
18. **Peloquin CA**, Jaresko GS, Yong CL, Keung ACF, Bulpitt AE, Jelliffe RW. Population Pharmacokinetic Modeling of Isoniazid, Rifampin, and Pyrazinamide. Antimicrobial Agents and Chemotherapy 1997; 41: 2670-2679.
23. **Peloquin CA**, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of Ethambutol Under Fasting Conditions, with Food, and with Antacids. Antimicrobial Agents and Chemotherapy 1999, 43; 568-572.
27. Malone RS, Fish DN, Spiegel DM, Childs JM, **Peloquin CA**. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med 1999; 159: 1580-1584.
38. Zhu M, Nix DE, Adam RD, Childs JM, **Peloquin CA**. Pharmacokinetics of Cycloserine under Fasting Conditions, with Orange Juice, Food, and Antacids. Pharmacotherapy 2001; 21: 891-897.

45. Spradling P, Drociuk D, McLaughlin S, Lee LM, **Peloquin CA**, Gallicano K, Pozsik C, Onorato I, Ridzon R. Drug-drug interactions in inmates treated for human immunodeficiency virus and *Mycobacterium tuberculosis* infection or disease: An institutional tuberculosis outbreak. *Clinical Infectious Diseases* 2002; 35: 1106-1112.
49. Weiner M, Burman W, Vernon A, Benator D, **Peloquin CA**, Khan A, Weis S, King B, Shah N, Hodge T and the Tuberculosis Trials Consortium. Low Isoniazid Concentration Associated with Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine. *Am J Respir Crit Care Med*. 2003 Jan 16 [e-pub ahead of print]; print version *Am J Respir Crit Care Med*. 2003; 167: 1341-1347.
53. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, **Peloquin CA**, Rimmel RP, Chirgwin K, Salomon N, Hafner R for the ACTG 309 Team. The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. *Clin Infect Dis* 2004; 38: 556-564.
60. Weiner M, Benator D, Burman W, **Peloquin CA**, Khan A, Vernon A, Jones B S, Silva-Trigo C, Zhao Z, Hodge T and the Tuberculosis Trials Consortium. Association Between Acquired Rifamycin Resistance and the Pharmacokinetics of Rifabutin and Isoniazid among Patients with HIV and Tuberculosis. *Clinical Infectious Diseases* 2005; 40: 1481-1491.
62. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold A, Lockman S, Oyeri R, Talbot E, Kenyon T, Moetti T, Moffat H, **Peloquin CA**. Serum Concentrations of Antimycobacterial Drugs in Patients with Pulmonary Tuberculosis in Botswana. *Clinical Infectious Diseases* 2005; 41: 461-469.
68. Rosenthal IM, Williams K, Tyagi S, **Peloquin CA**, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. *Am J Respir Crit Care Med* 2006 Mar 30; [Epub ahead of print]; *Am J Respir Crit Care Med* 2006; 174: 94-101.
69. Johnson JL, Hadad DJ, Boom WH, Daley CL, **Peloquin CA**, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R. Early and Extended Early Bactericidal Activity of Levofloxacin, Gatifloxacin and Moxifloxacin in Pulmonary Tuberculosis. *Int J Tuberc Lung Dis* 2006; 10: 605-612.
71. Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, **Peloquin CA**, Bishai WR, Grosset JH. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in the murine model of tuberculosis. *Antimicrobial Agents and Chemotherapy* 2006; 50: 2621-2625.
75. Weiner M, Burman W, Luo CC, **Peloquin CA**, Engle M, Goldberg S, Agarwal V, Vernon A. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. *Antimicrob Agents Chemother* 2007 May 21; [Epub ahead of print]; *Antimicrob Agents Chemother* 2007; 51: 2861-2866.
79. **Peloquin CA**, Hadad DJ, Molion LPD, Palaci M, Boom WH, Dietze R, Johnson JL. Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in Adults with Pulmonary Tuberculosis. *Antimicrobial Agents and Chemotherapy* 2007 Dec 10; [Epub ahead of print]
80. Rosenthal I, Zhang M, Williams KN, **Peloquin CA**, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger E. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. *PLoS Medicine* 2007 Dec 18;4(12):e344 [Epub ahead of print]
81. Am Ende CW, Knudson SE, Liu N, Childs J, Sullivan TJ, Boyne M, Xu H, Gegina Y, Knudson DL, Johnson F, **Peloquin CA**, Slayden RA, Tonge PJ. Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. *Bioorg Med Chem Lett*. 2008 Apr 18. [Epub ahead of print]
86. Dooley K, Flexner C, Hackman J, **Peloquin C**, Nuermberger E, Chaisson RE, Dorman SE. High-dose intermittent rifapentine induces its own metabolism and that of moxifloxacin. *Antimicrobial Agents and Chemotherapy* 2008 Sep 2. [Epub ahead of print]
87. Dietz R, Hadad DJ, McGee B, Molino LP, Maciel ELN, **Peloquin CA**, Johnson DF, Debanne SM, Eisenach K, Boom H, Palaci M, Johnson JL. Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis. *Am J Respir Crit Care Med*. 2008 Dec 1;178(11):1180-1185. Epub 2008 Sep 11.
88. Sung JC, Garcia-Contreras L, VerBerkmoes JL, **Peloquin CA**, Elbert KJ, Hickey AJ, Edwards DE. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. *Antimicrobial Agents and Chemotherapy* 2009; 53: 1338-1343. [Jan 12 e-pub]

Principal Investigator/Program Director (Last, First, Middle): PI Name